Reimbursement drug list total drugs vs Clinical trial registrations in China
In 2025, reimbursement drug list total drugs in China stood at 3,253, against 5,215 for clinical trial registrations.
Change the pair
Compare different indicators
The series
Over time
China, spaced by time. Both series are in count, so they share one axis; the legend names each line.
Reimbursement drug list total drugs and Clinical trial registrations
Unit: count · 6 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| Reimbursement drug list total drugs | as of 7 Dec 2025 | Actual | 3,253 |
| Reimbursement drug list total drugs | as of 28 Nov 2024 | Actual | 3,159 |
| Clinical trial registrations | 2025 | Actual | 5,215 |
| Clinical trial registrations | 2023 | Actual | 4,300 |
| Clinical trial registrations | 2022 | Actual | 3,410 |
| Clinical trial registrations | 2021 | Actual | 3,358 |
Shared periods
Side by side
Only one period is published for both series in China. Comparing anything else would mean comparing different years.
Provenance
Where these numbers come from
Reimbursement drug list total drugs
Total number of pharmaceutical products covered by a national or public reimbursement drug formulary.
2 observations in China · source organisations: State Council
Clinical trial registrations
Number of clinical trials registered on the International Clinical Trials Registry Platform.
4 observations in China · source organisations: State Council, NHSA
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring